ClinicalTrials.gg
CompletedNCT00373490Updated Aug 27, 2015Results posted

A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048)

A Phase 1 interventional study of Vorinostat and Vorinostat in Tumors, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-08-27.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Study summary

This is a clinical study to evaluate the safety and pharmacokinetics of an overseas determined maximum tolerated dose (MTD) of MK-0683 (vorinostat) in a Japanese patient population with solid tumors.

02

Conditions studied

  • Tumors

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 16 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with or cytologically diagnosed solid tumor in whom no standard therapy is available or the is to standard therapy

Exclusion criteria

Exclusion Criteria:

  • Patients with history of immunotherapy, radiotherapy, surgery, or chemotherapy during the previous 4 weeks
  • Any uncontrolled concomitant illness
  • Pregnant or breast-feeding
  • Serious drug or food allergy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Vorinostat 600 mg

    600 mg daily (300 mg twice daily \[b.i.d.\]) for 3 consecutive days followed by 4 days of rest.

    Drug: Vorinostat

  • Experimental
    Vorinostat 400 mg

    400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.

    Drug: Vorinostat

Interventions

  • 600 mg daily (300 mg twice daily \[b.i.d.\]) for 3 consecutive days followed by 4 days of rest.

    Also known as: MK-0683, Suberoylanilide Hydroxamic Acid (SAHA)

  • 400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.

    Also known as: MK-0683, Suberoylanilide Hydroxamic Acid (SAHA)

06

What researchers measure

Primary outcomes

  1. Number of Participants With a Dose Limiting Toxicity (DLT)

    Dose Limiting Toxicity = Drug-related side effects that are serious enough to prevent an increase in dose or level of that treatment

    Time frame: 21 Days (first cycle)

Secondary outcomes

  1. Area Under the Curve (AUC(0-infinity)) at Day 1 (600 mg and 400 mg)

    Area Under Curve (AUC(0-infinity))=Area under the plasma concentration versus time curve (AUC) from time zero to extrapolated infinite time (o- ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). At 600 mg, t=12 hours and at 400 mg, t=24 hours.

    Time frame: Day 1 (600 mg and 400 mg)

  2. Area Under the Curve (AUC(0-infinity)) at Day 3 (600 mg)

    Area Under Curve (AUC(0-infinity))=Area under the plasma concentration versus time curve (AUC) from time zero to 24 hours. It is obtained from AUC (0 - 12) plus AUC (12 - ∞)

    Time frame: Day 3 (600 mg)

  3. Area Under the Curve (AUC(0-infinity) at Day 21 (400 mg)

    Area Under Curve (AUC(0-infinity))=Area under the plasma concentration versus time curve (AUC) from time zero to 24 hours. It is obtained from AUC (0 - 24) plus AUC (24 - ∞)

    Time frame: Day 21 (400 mg)

  4. Maximum Concentration (Cmax) at Day 1 (600 mg and 400 mg)

    Time frame: Day 1 (600 mg and 400 mg)

  5. Maximum Concentration (Cmax) at Day 3 (600 mg)

    Time frame: Day 3 (600 mg)

  6. Maximum Concentration (Cmax) at Day 21 (400 mg)

    Time frame: Day 21 (400 mg)

07

Results

Posted May 20, 2009

Participant flow

Phase I. First participant started on study therapy on 18-Jul-2006. Study was multicenter (total of 3 sites).

Participant flow — Overall Study
MilestoneVorinostat 600 mgVorinostat 400 mg
Started106
Completed10
Not completed96
Withdrew: Adverse event01
Withdrew: Lack of efficacy94
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryNumber of Participants With a Dose Limiting Toxicity (DLT)

Dose Limiting Toxicity = Drug-related side effects that are serious enough to prevent an increase in dose or level of that treatment

Time frame:
21 Days (first cycle)
Reported as:
Number · Participants
Number of Participants With a Dose Limiting Toxicity (DLT)
ParticipantsVorinostat 600 mgVorinostat 400 mg
Number of Participants With a Dose Limiting Toxicity (DLT)02
SecondaryArea Under the Curve (AUC(0-infinity)) at Day 1 (600 mg and 400 mg)

Area Under Curve (AUC(0-infinity))=Area under the plasma concentration versus time curve (AUC) from time zero to extrapolated infinite time (o- ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). At 600 mg, t=12 hours and at 400 mg, t=24 hours.

Time frame:
Day 1 (600 mg and 400 mg)
Reported as:
Geometric mean · μM·hr
Area Under the Curve (AUC(0-infinity)) at Day 1 (600 mg and 400 mg)
μM·hrVorinostat 600 mgVorinostat 400 mg
Area Under the Curve (AUC(0-infinity)) at Day 1 (600 mg and 400 mg)3.94 ± 1.567.75 ± 2.79
SecondaryArea Under the Curve (AUC(0-infinity)) at Day 3 (600 mg)

Area Under Curve (AUC(0-infinity))=Area under the plasma concentration versus time curve (AUC) from time zero to 24 hours. It is obtained from AUC (0 - 12) plus AUC (12 - ∞)

Time frame:
Day 3 (600 mg)
Reported as:
Geometric mean · μM·hr
Area Under the Curve (AUC(0-infinity)) at Day 3 (600 mg)
μM·hrVorinostat 600 mgVorinostat 400 mg
Area Under the Curve (AUC(0-infinity)) at Day 3 (600 mg)4.15 ± 2.15—
SecondaryArea Under the Curve (AUC(0-infinity) at Day 21 (400 mg)

Area Under Curve (AUC(0-infinity))=Area under the plasma concentration versus time curve (AUC) from time zero to 24 hours. It is obtained from AUC (0 - 24) plus AUC (24 - ∞)

Time frame:
Day 21 (400 mg)
Reported as:
Geometric mean · μM·hr
Area Under the Curve (AUC(0-infinity) at Day 21 (400 mg)
μM·hrVorinostat 600 mgVorinostat 400 mg
Area Under the Curve (AUC(0-infinity) at Day 21 (400 mg)—8.3 ± 0.04
SecondaryMaximum Concentration (Cmax) at Day 1 (600 mg and 400 mg)
Time frame:
Day 1 (600 mg and 400 mg)
Reported as:
Geometric mean · μM
Maximum Concentration (Cmax) at Day 1 (600 mg and 400 mg)
μMVorinostat 600 mgVorinostat 400 mg
Maximum Concentration (Cmax) at Day 1 (600 mg and 400 mg)1.17 ± 0.431.62 ± 0.52
SecondaryMaximum Concentration (Cmax) at Day 3 (600 mg)
Time frame:
Day 3 (600 mg)
Reported as:
Geometric mean · μM
Maximum Concentration (Cmax) at Day 3 (600 mg)
μMVorinostat 600 mgVorinostat 400 mg
Maximum Concentration (Cmax) at Day 3 (600 mg)1.32 ± 0.75—
SecondaryMaximum Concentration (Cmax) at Day 21 (400 mg)
Time frame:
Day 21 (400 mg)
Reported as:
Geometric mean · μM
Maximum Concentration (Cmax) at Day 21 (400 mg)
μMVorinostat 600 mgVorinostat 400 mg
Maximum Concentration (Cmax) at Day 21 (400 mg)—2.04 ± 0.78

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vorinostat 600 mg—4/10 (40%)10/10 (100%)
Vorinostat 400 mg—0/6 (0%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventVorinostat 600 mgVorinostat 400 mg
ABDOMINAL PAINGastrointestinal disorders2/100/6
DIARRHOEAGastrointestinal disorders1/100/6
VOMITINGGastrointestinal disorders1/100/6
DISEASE PROGRESSIONGeneral disorders1/100/6
HYPERBILIRUBINAEMIAHepatobiliary disorders1/100/6
Most frequent other events
Showing 10 of 94
Most frequent other events
EventVorinostat 600 mgVorinostat 400 mg
NAUSEAGastrointestinal disorders8/106/6
PLATELET COUNT DECREASEDInvestigations3/106/6
ANOREXIAMetabolism and nutrition disorders9/106/6
VOMITINGGastrointestinal disorders5/105/6
BLOOD CREATININE INCREASEDInvestigations5/105/6
BLOOD GLUCOSE INCREASEDInvestigations6/105/6
FATIGUEGeneral disorders8/104/6
LYMPHOCYTE COUNT DECREASEDInvestigations5/104/6
CONSTIPATIONGastrointestinal disorders6/101/6
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations6/103/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Vorinostat 600 mgVorinostat 400 mgTotal
Mean60.2 ± 8.453.3 ± 1257.6 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Vorinostat 600 mgVorinostat 400 mgTotal
Female224
Male8412
Prior chemotherapy regimens
Prior chemotherapy regimens(Number of prior chemotherapy regimens)Vorinostat 600 mgVorinostat 400 mgTotal
Median3.5 (2 to 6)4.5 (3 to 6)4 (2 to 6)
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Doi T, Hamaguchi T, Shirao K, Chin K, Hatake K, Noguchi K, Otsuki T, Mehta A, Ohtsu A. Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial. Int J Clin Oncol. 2013 Feb;18(1):87-95. doi: 10.1007/s10147-011-0348-6. Epub 2012 Jan 11. PubMed 22234637 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.

Results were first posted in May 2009, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2006
First posted
Sep 8, 2006
Start
Jul 2006
Primary completionActual
Oct 2007
CompletionActual
Oct 2007
Results first posted
May 20, 2009
Last update
Aug 27, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00373490
Responsible party
Sponsor
First posted
Sep 8, 2006
Start date
Jul 2006
Primary completion
Oct 2007
Completion
Oct 2007
Results posted
May 20, 2009
Last update
Aug 27, 2015

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorinostat

Start the discussion